{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:22:39Z","timestamp":1787678559666,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012164","name":"National High-tech Research and Development Program","doi-asserted-by":"publisher","award":["2025-PUMCH-D-003"],"award-info":[{"award-number":["2025-PUMCH-D-003"]}],"id":[{"id":"10.13039\/501100012164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22176016"],"award-info":[{"award-number":["22176016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110236","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:41:24Z","timestamp":1783467684000},"page":"110236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics"],"prefix":"10.1016","volume":"180","author":[{"given":"Wenbin","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110236_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110236_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41391-024-00906-z","article-title":"Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey","volume":"28","author":"McManus","year":"2025","journal-title":"Prostate Cancer P D"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate Cancer: a systematic review","volume":"87","author":"Francini","year":"2025","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110236_bb0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2024.09.005","article-title":"Molecular hallmarks of prostate-specific membrane antigen in treatment-na\u00efve prostate cancer","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110236_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2967\/jnumed.120.260455","article-title":"(68)ga-PSMA-11 NDA approval: a novel and successful academic partnership","volume":"62","author":"Carlucci","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s41181-024-00317-4","article-title":"A comparison of routine [(68)ga]ga-PSMA-11 preparation using Locametz and Illuccix kits","volume":"9","author":"Wang","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110236_bb0040","first-page":"13n","article-title":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110236_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.semnuclmed.2024.02.007","article-title":"Prostate Cancer Theranostics with (177)Lu-PSMA","volume":"54","author":"Ahmadzadehfar","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.bioorg.2026.110236_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","article-title":"Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor","volume":"59","author":"Zha","year":"2018","journal-title":"Nucl. Med. Biol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110236_bb0055","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00259-023-06283-4","article-title":"A prospective head-to-head comparison of [(68)ga]ga-P16-093 and [(68)ga]ga-PSMA-11 PET\/CT in patients with primary prostate cancer","volume":"50","author":"Wang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110236_bb0060","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","article-title":"Preliminary evaluation of (68)ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate Cancer","volume":"24","author":"Lee","year":"2022","journal-title":"Mol. Imaging Biol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110236_bb0065","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1021\/acs.molpharmaceut.0c00777","article-title":"Synthesis and evaluation of (68)ga- and (177)Lu-Labeled (R)- vs (S)-DOTAGA prostate-specific membrane antigen-targeting derivatives","volume":"17","author":"Zhao","year":"2020","journal-title":"Mol. Pharm."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110236_bb0070","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1021\/acs.jmedchem.2c00852","article-title":"New PSMA-targeting ligands: transformation from diagnosis (ga-68) to radionuclide therapy (Lu-177)","volume":"65","author":"Zha","year":"2022","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110236_bb0075","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00259-024-06721-x","article-title":"Comparison of novel PSMA-targeting [(177)Lu]Lu-P17-087 with its albumin binding derivative [(177)Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study","volume":"51","author":"Li","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110236_bb0080","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1021\/acs.molpharmaceut.4c00020","article-title":"Novel [(68)ga\/(177)Lu]ga\/Lu-AZ-093 as PSMA-targeting agent for diagnosis and radiotherapy","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110236_bb0085","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1021\/acs.jmedchem.4c01420","article-title":"(68)ga\/(177)Lu-Labeled bivalent agents for targeting hypoxia and PSMA-binding in prostate Cancer","volume":"67","author":"Luo","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2967\/jnumed.125.270703","article-title":"First-in-human PET imaging of prostate Cancer using [(68)ga]ga-AZ-093 and its nitroimidazole-conjugated derivative [(68)ga]ga-AZ-NI-093","volume":"67","author":"Wang","year":"2026","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110236_bb0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0020-1693(00)80229-7","article-title":"Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles","volume":"190","author":"Clarke","year":"1991","journal-title":"Inorg. Chim. Acta"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110236_bb0105","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/acs.molpharmaceut.0c00103","article-title":"A new [(68)ga]ga-HBED-CC-bisphosphonate as a bone imaging agent","volume":"17","author":"Zha","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.110236_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2020.109485","article-title":"Development and validation of a kit formulation of [(68)ga]ga-P15-041 as a bone imaging agent","volume":"169","author":"Hong","year":"2021","journal-title":"Appl. Radiat. Isot."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110236_bb0115","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1021\/acs.jmedchem.3c02372","article-title":"Theranostic agent targeting bone metastasis: a novel [(68)ga]ga\/[(177)Lu]Lu-DOTA-HBED-bisphosphonate","volume":"67","author":"Jin","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110236_bb0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-024-06942-0","article-title":"First-in-human study of dosimetry, safety and efficacy for [(177)Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases","volume":"52","author":"Zhao","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"36","key":"10.1016\/j.bioorg.2026.110236_bb0125","doi-asserted-by":"crossref","first-page":"12711","DOI":"10.1021\/ja104591m","article-title":"A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules","volume":"132","author":"Zhang","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110236_bb0130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110236_bb0135","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","article-title":"Novel preclinical and radiopharmaceutical aspects of [68Ga]ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate Cancer","volume":"7","author":"Eder","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110236_bb0140","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1021\/mp500283k","article-title":"PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)cu, (68)ga, and (111)in","volume":"11","author":"Roosenburg","year":"2014","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110236_bb0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00259-011-1992-9","article-title":"Comparative evaluation of synthetic anti-HER2 affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts","volume":"39","author":"Malmberg","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110236_bb0150","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1039\/D5CS00392J","article-title":"Gallium-68-labeled radiopharmaceuticals: a review","volume":"54","author":"Tanwar","year":"2025","journal-title":"Chem. Soc. Rev."},{"issue":"78","key":"10.1016\/j.bioorg.2026.110236_bb0155","doi-asserted-by":"crossref","first-page":"49586","DOI":"10.1039\/C7RA09076E","article-title":"Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling","volume":"7","author":"Tsionou","year":"2017","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110236_bb0160","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1021\/acs.bioconjchem.2c00364","article-title":"H4picooparobust chelate for 225Ac\/111In theranostics","volume":"33","author":"Wharton","year":"2022","journal-title":"Bioconjug. Chem."},{"issue":"46","key":"10.1016\/j.bioorg.2026.110236_bb0165","doi-asserted-by":"crossref","first-page":"14712","DOI":"10.1002\/anie.201709532","article-title":"An eighteen-membered macrocyclic ligand for Actinium-225 targeted alpha therapy","volume":"56","author":"Thiele","year":"2017","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bioorg.2026.110236_bb0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.nucmedbio.2022.05.004","article-title":"Synthesis and ex vivo biodistribution of two 68Ga-labeled tetrazine tracers: comparison of pharmacokinetics","volume":"114-115","author":"Lambidis","year":"2022","journal-title":"Nucl. Med. Biol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110236_bb0175","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1007\/s00259-022-05757-1","article-title":"(18)F- or (177)Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention","volume":"49","author":"Li","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:42:21Z","timestamp":1787676141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S0045206826007728"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110236","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110236"}}